Emmecell

Emmecell is a San Diego-based biotech developing regenerative cell therapies for ocular diseases using its proprietary Magnetic Cell Delivery (MCD) platform. This technology uses magnetic nanoparticles to guide and hold therapeutic cells at the target site, aiming to improve efficacy over traditional cell delivery methods. The company's lead candidate, EO2002, is a first-in-class, non-surgical cell injection for corneal edema, positioning it to address a major unmet need in corneal transplantation. Emmecell also operates a subsidiary, CellMP, which provides cGMP manufacturing services for cell therapies to other biotech companies.

Magnetic Cell Delivery (MCD) nanoparticle platform: uses magnetic nanoparticles attached to therapeutic cells and an external magnetic field to guide, localize, and retain cells at the target tissue site to improve integration and efficacy.

In the non-surgical treatment of corneal edema, direct competition is currently limited, positioning EO2002 as a potential first-in-class therapy. However, it competes indirectly with the established standard of care: various forms of corneal transplant surgery. Other companies are exploring cell therapies and pharmacological treatments for corneal diseases, but few have a focused delivery platform like MCD.